Literature DB >> 21880454

Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice.

Silpa Nuthalapati1, Ping Guo, Qingyu Zhou, M V Ramana Reddy, E Premkumar Reddy, James M Gallo.   

Abstract

ON01910 is a small molecular weight benzyl styryl sulfone currently under investigation as a novel anticancer agent. The purpose of the investigation was to develop a sensitive and reproducible liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to quantitate levels of ON01910 in small amounts of five biological matrices; mouse plasma, feces, urine, normal brain and brain tumor. For all matrices, protein precipitation sample preparation was used that led to linear calibration curves with coefficients of determination greater than 0.99. The lower limit of quantitation (LLOQ) for all matrices was 5 ng/ml except that for mouse urine which was 10 ng/ml. The calibration standard curves were reproducible for all matrices with inter- and intra-day variability in precision and accuracy being less than 15% at all quality control concentrations except for the LLOQ in mouse plasma for which the accuracy was within 17%. The assay was successfully applied to characterize the systemic pharmacokinetics of ON01910 as well as its disposition in brain and brain tumor in mice. ON01910 exhibited a clearance of 3.61±0.85 l/h/kg and a half life of 8.66±3.30 h at 50 mg/kg dose given I.V.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880454      PMCID: PMC3176944          DOI: 10.1016/j.jpba.2011.08.003

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 2.  Blood-brain barrier interfaces and brain tumors.

Authors:  Sae-Won Lee; Woo Jean Kim; Jeong Ae Park; Yoon Kyung Choi; Yoo-Wook Kwon; Kyu-Won Kim
Journal:  Arch Pharm Res       Date:  2006-04       Impact factor: 4.946

3.  ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

Authors:  Kiranmai Gumireddy; M V Ramana Reddy; Stephen C Cosenza; R Boominathan; R Boomi Nathan; Stacey J Baker; Nabisa Papathi; Jiandong Jiang; James Holland; E Premkumar Reddy
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

4.  Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.

Authors:  Jing Li; Ming Zhao; Antonio Jimeno; Ping He; M V Ramana Reddy; Manuel Hidalgo; Ross C Donehower; Michelle A Rudek
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-06-07       Impact factor: 3.205

5.  Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.

Authors:  Amy W Chun; Stephen C Cosenza; David R Taft; Manoj Maniar
Journal:  Cancer Chemother Pharmacol       Date:  2009-05-24       Impact factor: 3.333

  5 in total
  1 in total

1.  Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy.

Authors:  Silpa Nuthalapati; Qingyu Zhou; Ping Guo; Hua Lv; Stephen Cosenza; M V Ramana Reddy; E Premkumar Reddy; James M Gallo
Journal:  Pharm Res       Date:  2012-06-08       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.